Cart is empty Psilocybin, the active ingredient in psychedelic mushrooms, shows promise for the transitional treatment of episodic migraines in early clinical trials, according to a review from Yale School of Medicine’s Emmanuelle Schindler, M.D., Ph.D.
Psilocybin, the active ingredient in psychedelic mushrooms, shows promise for the transitional treatment of episodic migraines in early clinical trials, according to a review from Yale School of Medicine’s Emmanuelle Schindler, M.D., Ph.D.
Leave A Comment